Crossmark

Digital Therapeutics for MCI and Alzheimer's disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer's Disease conference (CTAD)

Crossref DOI link: https://doi.org/10.14283/jpad.2022.28

Published Print: 2022-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Shuren, J.

Doraiswamy, P.M.
License Information

Text and Data Mining valid from 2022-04-01

Text and Data Mining valid from 2022-04-01

Version of Record valid from 2024-09-25
More Information

This article is maintained by: Elsevier

Article Title: Digital Therapeutics for MCI and Alzheimer's disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer's Disease conference (CTAD)

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2022.28

Content Type: simple-article

Copyright: Copyright © 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below